The Pediatric Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Pediatric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pediatric Cancer. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pediatric Cancer - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pediatric Cancer and features dormant and discontinued products.

GlobalData tracks seven drugs in development for Pediatric Cancer by seven companies/universities/institutes. The top development phase for Pediatric Cancer is preclinical with three drugs in that stage. The Pediatric Cancer pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pediatric Cancer pipeline products market are: Applied Research using OMIC Sciences, BioMarck Pharmaceuticals and Orphelia Pharma.

The key targets in the Pediatric Cancer pipeline products market include DNA, Serine/Threonine Protein Kinase VRK1 (Vaccinia Related Kinase 1 or VRK1 or EC, and Thymidylate Synthase (TYMS or EC

The key mechanisms of action in the Pediatric Cancer pipeline product include DNA Synthesis Inhibitor with two drugs in Phase I. The Pediatric Cancer pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Pediatric Cancer pipeline products market including Small Molecule, and Synthetic Peptide.

Pediatric Cancer overview

Pediatric cancer types include leukemias, brain and other central nervous system (CNS) tumors, and lymphomas. Signs and symptoms include unexplained paleness and loss of energy, easy bruising or bleeding, limping, fever, and headaches. Diagnosis can be done by blood tests, biopsy, ultrasound, MRI, and PET-CT scan. Common treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and stem cell transplant.

For a complete picture of Pediatric Cancer’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.